Search

Your search keyword '"Aitken, Samuel L"' showing total 435 results
Start Over Author "Aitken, Samuel L"
435 results on '"Aitken, Samuel L"'

3. Treatment of Multidrug-Resistant Vancomycin-Resistant Enterococcus faecium Hardware-Associated Vertebral Osteomyelitis with Oritavancin plus Ampicillin.

Author

Dahesh, Samira, Wong, Brian, Nizet, Victor, Sakoulas, George, Tran, Truc T, and Aitken, Samuel L

Subjects
Antimicrobial Resistance, Infectious Diseases, Ampicillin, Anti-Bacterial Agents, Drug Resistance, Multiple, Bacterial, Drug Synergism, Enterococcus faecium, Gram-Positive Bacterial Infections, Humans, Lipoglycopeptides, Male, Microbial Sensitivity Tests, Middle Aged, Osteomyelitis, Vancomycin, Vancomycin-Resistant Enterococci, ampicillin, oritavancin, vancomycin-resistant Enterococcus faecium, vancomycin-resistant Enterococcus faecium, Microbiology, Medical Microbiology, Pharmacology and Pharmaceutical Sciences
Abstract

Weekly oritavancin plus ampicillin continuous infusion combination therapy was used to successfully treat a deep spine vancomycin-resistant Enterococcus faecium infection associated with hardware. Checkerboard and time-kill assays confirmed synergy between these two antibiotics. Further synergies of oritavancin and ampicillin with rifampin or the endogenous human antimicrobial peptide cathelicidin LL-37 were demonstrated.

Published
2019

4. The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States—Is There a Potential Role for Durlobactam?

Author

Aitken, Samuel L, Pierce, Virginia M, Pogue, Jason M, Kline, Ellen G, Tverdek, Frank P, and Shields, Ryan K

Subjects
*ENZYME metabolism, *COMBINATION drug therapy, *MICROBIAL sensitivity tests, *BETA lactam antibiotics, *ESCHERICHIA coli, *ESCHERICHIA coli diseases, *GENETIC mutation, *BETA lactamases, *AZTREONAM, *CEPHALOSPORINS
Abstract

We report identification of 5 patients with infections caused by NDM-5-producing Escherichia coli harboring PBP3 mutations that showed reduced susceptibility to aztreonam-avibactam and cefiderocol. Durlobactam, a novel diazabicyclooctane β-lactamase inhibitor, demonstrated minimum inhibitory concentrations ranging from 0.5 to 2 µg/mL supporting future investigations into a potential role in clinical management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Analgosedation: The use of Fentanyl Compared to Hydromorphone

Author

Choi Hahnl, Radparvar Sara, Aitken Samuel L., and Altshuler Jerry

Subjects
analgosedation, sedation, analgesic, pain, agitation, Medical emergencies. Critical care. Intensive care. First aid, RC86-88.9
Abstract

The 2018 Society of Critical Care Medicine guidelines on the “Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU” advocate for protocol-based analgosedation practices. There are limited data available to guide which analgesic to use. This study compares outcomes in patients who received continuous infusions of fentanyl or hydromorphone as sedative agents in the intensive care setting.

Published
2021
Full Text
View/download PDF

8. Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185

Author

Kawai, Akito, primary, Shropshire, William C., additional, Suzuki, Masahiro, additional, Borjan, Jovan, additional, Aitken, Samuel L., additional, Bachman, William C., additional, McElheny, Christi L., additional, Bhatti, Micah M., additional, Shields, Ryan K., additional, Shelburne, Samuel A., additional, and Doi, Yohei, additional

Published
2024
Full Text
View/download PDF

12. Implementation of an Automated Antibiotic Time-out at a Comprehensive Cancer Center.

Author

Tverdek, Frank P, Aitken, Samuel L, Mulanovich, Victor E, Adachi, Javier, Wu, Cai, Cantu, Sherry S, McDaneld, Patrick M, and Chemaly, Roy F

Subjects
*ANTIBIOTICS, *TIME series analysis, *MEROPENEM, *ELECTRONIC health records, *TIGECYCLINE
Abstract

Background Antimicrobial stewardship programs can optimize antimicrobial use and have been federally mandated in all hospitals. However, best stewardship practices in immunocompromised patients with cancer are not well established. Methods An antimicrobial time out, in the form of an email, was sent to physicians caring for hospitalized patients reaching 5 days of therapy for targeted antimicrobials (daptomycin, linezolid, tigecycline, vancomycin, imipenem/cilastatin, meropenem) in a comprehensive cancer center. Physicians were to discontinue the antimicrobial if unnecessary or document a rationale for continuation. This is a quasi-experimental, interrupted time series analysis assessing antimicrobial use during the following times: period 1 (before time-out: January 2007-June 2010) and period 2 (after time-out: July 2010-March/2015). The primary antimicrobial consumption metric was mean duration of therapy. Days of therapy per 1000 patient-days were also assessed. Results Implementation of the time-out was associated with a significant decrease in mean duration of therapy for the following antimicrobials; daptomycin: −0.89 days (95% confidence interval [CI], −1.38 to −.41); linezolid: −0.89 days (95% CI, −1.27 to −.52); meropenem: −0.97 days (95% CI, −1.39 to −.56); tigecycline: −1.41 days (95% CI, −2.19 to −.63); P <.001 for each comparison. Days of therapy/1000 patient-days decreased significantly for meropenem (−43.49; 95% CI, −58.61 to −28.37; P <.001), tigecycline (−35.47; 95% CI, −44.94 to −26.00; P <.001), and daptomycin (−9.47; 95% CI, −15.25 to −3.68; P =.002). Discussion A passive day 5 time-out was associated with reduction in targeted antibiotic use in a cancer center and could potentially be successfully adopted to several settings and electronic health records. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. 1109. A multicenter, observational study to compare the effectiveness of Ceftazidime-Avibactam versus Ceftolozane-Tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the United States (CACTUS)

Author

Shields, Ryan K, primary, Abbo, Lilian M, additional, Ackley, Renee, additional, Aitken, Samuel L, additional, Albrecht, Benjamin, additional, Babiker, Ahmed, additional, Cifuentes, Renzo, additional, Claeys, Kimberly C, additional, DeSear, Kathryn, additional, Gallagher, Jason C, additional, Gregory, Eric, additional, Heil, Emily L, additional, Hickey, Carissa, additional, Klatt, Megan, additional, Kline, Ellen G, additional, Kubat, Ryan C, additional, Kufel, Wesley D, additional, Hyoung Lee, Jae, additional, Lim, Ahmi, additional, Lingg, Theresa, additional, MacDougall, Conan, additional, Mathers, Amy, additional, McCreary, Erin K, additional, Moore, William J, additional, Olson, Shannon, additional, Oxer, Jessica, additional, Pearson, Jeffrey C, additional, Pham, Christine, additional, Polk, Christopher, additional, Satlin, Michael J, additional, Satola, Sarah W, additional, Shah, Sunish, additional, Solanki, Yash B, additional, Tamma, Pranita, additional, Vega, Ana, additional, Veena, Venugopalan, additional, Veve, Michael, additional, Wangchinda, Walaiporn, additional, Witt, Lucy S, additional, Wu, Janet, additional, and Pogue, jason M, additional

Published
2023
Full Text
View/download PDF

19. Clonal Emergence of Invasive Multidrug-Resistant Staphylococcus epidermidis Deconvoluted via a Combination of Whole-Genome Sequencing and Microbiome Analyses

Author

Li, Xiqi, Arias, Cesar A., Aitken, Samuel L., Peña, Jessica Galloway, Panesso, Diana, Chang, Michael, Diaz, Lorena, Rios, Rafael, Numan, Yazan, Ghaoui, Sammi, DebRoy, Sruti, Bhatti, Micah M., Simmons, Dawn E., Raad, Isaam, Hachem, Ray, Folan, Stephanie A., Sahasarabhojane, Pranoti, Kalia, Awdhesh, and Shelburne, Samuel A.

Published
2018

23. High-level ceftazidime/avibactam resistance in Escherichia coli conferred by the novel plasmid-mediated β-lactamase CMY-185 variant

Author

Shropshire, William C, primary, Endres, Bradley T, additional, Borjan, Jovan, additional, Aitken, Samuel L, additional, Bachman, William C, additional, McElheny, Christi L, additional, Wu, Chin-Ting, additional, Egge, Stephanie L, additional, Khan, Ayesha, additional, Miller, William R, additional, Bhatti, Micah M, additional, Saharasbhojane, Pranoti, additional, Kawai, Akito, additional, Shields, Ryan K, additional, Shelburne, Samuel A, additional, and Doi, Yohei, additional

Published
2023
Full Text
View/download PDF

27. Nut Cracked? Does the ACORN Trial End the Debate Surrounding Vancomycin and Piperacillin-Tazobactam Combination Therapy and Increased Risk for Acute Kidney Injury?

Author

Pogue, Jason M and Aitken, Samuel L

Subjects
*ACUTE kidney failure, *ACORNS, *VANCOMYCIN, *DEATH rate
Abstract

Observational data published over the past decade have suggested that concomitant receipt of piperacillin-tazobactam with vancomycin significantly increases the risk for vancomycin-associated acute kidney injury. Importantly, however, there is significant controversy surrounding this association, and debate continues about the veracity of the risk. Given this ongoing debate, the recently published "Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial" is of tremendous interest to the infectious diseases community. In ACORN, the authors conclude that there was no association between receipt of cefepime or piperacillin-tazobactam and the primary outcome of acute kidney injury or death by day 14, despite the fact that >75% of the population received concomitant vancomycin. In this perspective, we provide a brief history on the controversy, provide a critical analysis of the ACORN findings, and ultimately discuss how these data help inform the ongoing debate. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)

Author

Tamma, Pranita D, Aitken, Samuel L, Bonomo, Robert A, Mathers, Amy J, van Duin, David, and Clancy, Cornelius J

Subjects
Microbiology (medical), IDSA Features, Microbial Sensitivity Tests, Communicable Diseases, United States, beta-Lactamases, Anti-Bacterial Agents, Cephalosporins, Infectious Diseases, Carbapenems, Pseudomonas aeruginosa, Humans, Child, Azabicyclo Compounds
Abstract

Background The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. The initial guidance document on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) was published on 17 September 2020. Over the past year, there have been a number of important publications furthering our understanding of the management of ESBL-E, CRE, and DTR-P. aeruginosa infections, prompting a rereview of the literature and this updated guidance document. Methods A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections reviewed, updated, and expanded previously developed questions and recommendations about the treatment of ESBL-E, CRE, and DTR-P. aeruginosa infections. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results Preferred and alternative treatment recommendations are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, duration of therapy, and other management considerations are also discussed briefly. Recommendations apply for both adult and pediatric populations. Conclusions The field of antimicrobial resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial-resistant infections. This document is current as of 24 October 2021. The most current versions of IDSA documents, including dates of publication, are available at www.idsociety.org/practice-guideline/amr-guidance/.

Published
2022

32. High-level ceftazidime-avibactam resistance inEscherichia coliconferred by the novel plasmid-mediated beta-lactamase CMY-185 variant

Author

Shropshire, William C., primary, Endres, Bradley T., additional, Borjan, Jovan, additional, Aitken, Samuel L., additional, Bachman, William C., additional, McElheny, Christi L., additional, Khan, Ayesha, additional, Bhatti, Micah M., additional, Saharasbhojane, Pranoti, additional, Kawai, Akito, additional, Shields, Ryan K., additional, Shelburne, Samuel A., additional, and Doi, Yohei, additional

Published
2023
Full Text
View/download PDF

35. Clinical characteristics, microbiology and outcomes of a cohort of patients treated with ceftolozane/tazobactam in acute care inpatient facilities, Houston, Texas, USA

Author

Tran, Truc T, primary, Cabrera, Nicolo L, additional, Gonzales-Luna, Anne J, additional, Carlson, Travis J, additional, Alnezary, Faris, additional, Miller, William R, additional, Sakurai, Aki, additional, Dinh, An Q, additional, Rydell, Kirsten, additional, Rios, Rafael, additional, Diaz, Lorena, additional, Hanson, Blake M, additional, Munita, Jose M, additional, Pedroza, Claudia, additional, Shelburne, Samuel A, additional, Aitken, Samuel L, additional, Garey, Kevin W, additional, Dillon, Ryan, additional, Puzniak, Laura, additional, and Arias, Cesar A, additional

Published
2022
Full Text
View/download PDF

39. Risk Factors Associated with Severe Clostridioides difficile Infection in Patients with Cancer

Author

Francisco, Denise Marie A., primary, Zhang, Liangliang, additional, Jiang, Ying, additional, Olvera, Adilene, additional, Adachi, Javier, additional, Guevara, Eduardo Yepez, additional, Aitken, Samuel L., additional, Garey, Kevin W., additional, Peterson, Christine B., additional, Do, Kim-Anh, additional, Dillon, Ryan, additional, Obi, Engels N., additional, Jenq, Robert, additional, and Okhuysen, Pablo C., additional

Published
2022
Full Text
View/download PDF

45. Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)

Author

Contreras, German A., Munita, Jose M., Simar, Shelby, Luterbach, Courtney, Dinh, An Q., Rydell, Kirsten, Sahasrabhojane, Pranoti, V, Rios, Rafael, Diaz, Lorena, Reyes, Katherine, Zervos, Marcus, Misikir, Helina M., Sanchez-Petitto, Gabriela, Liu, Catherine, Doi, Yohei, Abbo, Lilian M., Shimose, Luis, Seifert, Harald, Gudiol, Carlota, Barberis, Fernanda, Pedroza, Claudia, Aitken, Samuel L., Shelburne, Samuel A., Duin, Davidvan, Tran, Truc T., Hanson, Blake M., Arias, Cesar A., Contreras, German A., Munita, Jose M., Simar, Shelby, Luterbach, Courtney, Dinh, An Q., Rydell, Kirsten, Sahasrabhojane, Pranoti, V, Rios, Rafael, Diaz, Lorena, Reyes, Katherine, Zervos, Marcus, Misikir, Helina M., Sanchez-Petitto, Gabriela, Liu, Catherine, Doi, Yohei, Abbo, Lilian M., Shimose, Luis, Seifert, Harald, Gudiol, Carlota, Barberis, Fernanda, Pedroza, Claudia, Aitken, Samuel L., Shelburne, Samuel A., Duin, Davidvan, Tran, Truc T., Hanson, Blake M., and Arias, Cesar A.

Abstract

Background Vancomycin-resistant enterococci (VRE) are major therapeutic challenges. Prospective contemporary data characterizing the clinical and molecular epidemiology of VRE bloodstream infections (BSIs) are lacking. Methods The Vancomycin-Resistant Enterococcal BSI Outcomes Study (VENOUS I) is a prospective observational cohort of adult patients with enterococcal BSI in 11 US hospitals. We included patients with Enterococcus faecalis or Enterococcus faecium BSI with >= 1 follow-up blood culture(s) within 7 days and availability of isolate(s) for further characterization. The primary study outcome was in-hospital mortality. Secondary outcomes were mortality at days 4, 7, 10, 12, and 15 after index blood culture. A desirability of outcome ranking was constructed to assess the association of vancomycin resistance with outcomes. All index isolates were subjected to whole genome sequencing. Results Forty-two of 232 (18%) patients died in hospital and 39 (17%) exhibited microbiological failure (lack of clearance in the first 4 days). Neutropenia (hazard ratio [HR], 3.13), microbiological failure (HR, 2.4), VRE BSI (HR, 2.13), use of urinary catheter (HR, 1.85), and Pitt BSI score >= 2 (HR, 1.83) were significant predictors of in-hospital mortality. Microbiological failure was the strongest predictor of in-hospital mortality in patients with E faecium bacteremia (HR, 5.03). The impact of vancomycin resistance on mortality in our cohort changed throughout the course of hospitalization. Enterococcus faecalis sequence type 6 was a predominant multidrug-resistant lineage, whereas a heterogeneous genomic population of E faecium was identified. Conclusions Failure of early eradication of VRE from the bloodstream is a major factor associated with poor outcomes. Failure to eradicate enterococci from the bloodstream in the first 4 days after the index blood culture was the most consistent factor associated with increased risk of mortality. The association of vancomycin resistanc

Published
2022

47. Oral and Stool Microbiome Coalescence and Its Association With Antibiotic Exposure in Acute Leukemia Patients

Author

Franklin, Samantha, primary, Aitken, Samuel L., additional, Shi, Yushi, additional, Sahasrabhojane, Pranoti V., additional, Robinson, Sarah, additional, Peterson, Christine B., additional, Daver, Naval, additional, Ajami, Nadim A., additional, Kontoyiannis, Dimitrios P., additional, Shelburne, Samuel A., additional, and Galloway-Peña, Jessica, additional

Published
2022
Full Text
View/download PDF

49. Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)

Author

Contreras, German A, primary, Munita, Jose M, additional, Simar, Shelby, additional, Luterbach, Courtney, additional, Dinh, An Q, additional, Rydell, Kirsten, additional, Sahasrabhojane, Pranoti V, additional, Rios, Rafael, additional, Diaz, Lorena, additional, Reyes, Katherine, additional, Zervos, Marcus, additional, Misikir, Helina M, additional, Sanchez-Petitto, Gabriela, additional, Liu, Catherine, additional, Doi, Yohei, additional, Abbo, Lilian M, additional, Shimose, Luis, additional, Seifert, Harald, additional, Gudiol, Carlota, additional, Barberis, Fernanda, additional, Pedroza, Claudia, additional, Aitken, Samuel L, additional, Shelburne, Samuel A, additional, van Duin, David, additional, Tran, Truc T, additional, Hanson, Blake M, additional, and Arias, Cesar A, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results